BLFS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioLife Solutions Inc (BLFS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, recent partnership, and positive analyst sentiment outweigh the short-term financial challenges. The technical indicators and options data suggest a neutral to slightly positive sentiment, making this a reasonable entry point for long-term growth potential.
The MACD histogram is positive at 0.0974, indicating a bullish trend, though it is contracting. RSI at 42.868 is neutral, showing no overbought or oversold conditions. Moving averages are converging, suggesting a consolidation phase. Key resistance levels are at 23.436 and 23.967, with support at 21.717 and 21.186. The stock closed at 23.72, slightly above the pivot point of 22.577, indicating mild bullish momentum.
Q4 2025 revenue increased by 20% YoY to $24.8 million.
New partnership with QKine Limited, enhancing its position in the cell and gene therapy market.
Analyst upgrade with a price target increase to $34 and an Outperform rating.
BioLife Solutions is structurally integrated into large pharma and biotech programs, providing long-term stability.
Net income dropped by -136.47% YoY in Q3 2025, indicating profitability challenges.
EPS also declined significantly by -125.00% YoY, reflecting weaker earnings performance.
Gross margin slightly decreased to 61.36%, down -1.37% YoY.
In Q3 2025, revenue grew by 31.21% YoY to $28.067 million, demonstrating strong top-line growth. However, net income fell to $621,000, a significant decline of -136.47% YoY, and EPS dropped to 0.01, down -125.00% YoY. Gross margin also declined slightly to 61.36%, down -1.37% YoY. For Q4 2025, revenue was reported at $24.8 million, a 20% YoY increase, showcasing continued growth.
Northland raised the price target to $34 from $31 and maintained an Outperform rating. The company is highlighted as a 2026 Top Pick due to its strategic positioning in the biopreservation layer of cell and gene therapy development, providing long-term growth potential.
